| Market Cap | 32.08M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.63M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 97.00% |
| Sales | 9.77M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 143.00% |
| Dividend | N/A | Price/Book | 4.50 | EPS next 5Y | - | 52W High Chg | -79.00% |
| Recommedations | - | Quick Ratio | 4.24 | Shares Outstanding | 17.67M | 52W Low Chg | 2,450.00% |
| Insider Own | 64.38% | ROA | -12.68% | Shares Float | 9.96M | Beta | 1.95 |
| Inst Own | 0.59% | ROE | -32.21% | Shares Shorted/Prior | 99.74K/20.06K | Price | 2.04 |
| Gross Margin | 13.61% | Profit Margin | -26.91% | Avg. Volume | 731,051 | Target Price | - |
| Oper. Margin | 7.36% | Earnings Date | - | Volume | 680,177 | Change | -2.39% |
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
